http://www.summitplc.com/
Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease Duchenne Muscular Dystrophy (DMD) and infections caused by the superbug C. difficile

Posted a week ago on ll - The last target set by this guy was broken for this reason. Charts don't work with news driven stock.

The reality is that Summit's peers in the USA are valued at what would equate to 85p or higher for Summit, this is the reason for the rise, particularly as Summit is now presenting it's finding to a US audience who tend to appreciate the work of BioTechs unlike in the UK.

I expect this stock to keep rising, and if anyone of it's lead drugs makes it to the market place, then it will be £2 per share, not 85-100p and certainly way above some chartists 20p! 12p made me laugh, so does 20p!

IMHO, DYOR etc

Muscular dystrophy drug from GlaxoSmithKline, Prosensa fails PhIII


September 20, 2013 | By John Carroll




http://www.fiercebiotech.com/story/muscular-dystrophy-drug-glaxosmithkline-prosensa-fails-phiii/2013-09-20

Sad for the families, may prove very good for Summit investors. Still a way to go yet.

A lot of excitement across the boards today about this share.

No stopping this one.

Summit Corporation PLC (SUMM:LSE) set a new 52-week high during today's trading session when it reached 19.18. Over this period, the share price is up 424.14%.

Yep, indeed!...going skyhigh....just like PLE....then hopefully LBB, MDZ, PIRI, COMS, CEE, QPP amongst others (already done well with REM having bought b4 the surge and have taken profits since)

sorry, that's CCE, not CEE!

22 Aug N+1 Singer 10.70 Buy - Looking dated now the sp is at 19p . As Delia Smith would say to N+1 Singer '' Lets be aving yer''. lol

APPOINTMENT OF NOMINATED ADVISER

Oxford, UK, 26 September 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, is pleased to announce the appointment with immediate effect of Cairn Financial Advisers as the Company's Nominated Adviser (Nomad).

- END -

Summit to present at California medical congress
By John Harrington September 30 2013, 2:05pm Summit is an Oxford based drug discovery and development company targeting high-value areas of unmet medical need including DMD and C. difficile infection.Summit is an Oxford based drug discovery and development company targeting high-value areas of unmet medical need including DMD and C. difficile infection.

Summit (LON:SUMM) is to give a presentation on one of its lead drugs at the 18th International World Muscle Society congress in California.

The poster presentation, entitled "Future clinical and biomarker development for SMT C1100, the first utrophin modulator to enter clinical trials for Duchenne Muscular Dystrophy", will outline the proposed clinical development plan to achieve proof of concept for SMT C1100 in Duchenne muscular dystrophy (DMD) patients.

Summit's C1100 development drug has the potential to maintain healthy muscle tone. This offers a potential breakthrough in treating DMD, a rare wasting disease that affects boys only (and 1,500 here in the UK).

Details will also be presented on the supporting biomarker programme that aims to develop new exploratory clinical endpoints to help evaluate the benefit of therapies such as SMT C1100 in future DMD patient trials.

The Congress is taking place from 1 October to 5 October.

A copy

A link to the above :- Summit to Present Clinical and Biomarker Programmes for DMD at WMS

A copy of the presentation put on the company website today -

http://www.summitplc.com/userfiles/file/WMS%202013%20FINAL(1).pdf

sp down 10% @13p profit taking?

A good 8% pull back today.

And another 10%

Summit Receives Regulatory Approval to Start Ph...

HUG


Summit Corporation plc
('Summit' or 'the Company')

SUMMIT RECEIVES REGULATORY APPROVAL TO START PHASE 1B CLINICAL TRIAL OF SMT C1100 IN DMD PATIENTS

Oxford, UK, 1 November 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection, announces that its Phase 1b Clinical Trial Application for SMT C1100 has received approval from the UK Medicines and Healthcare products Regulatory Agency ('MHRA') and the Ethics Review Committee. SMT C1100 is a small molecule utrophin modulator that has the potential to treat all patients with DMD, regardless of the underlying genetic fault.

"Securing regulatory approval for the first in patient Phase 1b clinical trial has achieved another important milestone in the development of utrophin modulator, SMT C1100, for DMD," commented Glyn Edwards, Chief Executive Officer. "We believe that utrophin modulation is a novel disease-modifying approach for all boys with DMD and this Phase 1b trial forms an integral part of our wider clinical plans towards establishing SMT C1100 as a viable treatment for this devastating condition."

The Phase 1b trial will be a dose-escalating, open-label study and will be conducted in a total of 12 paediatric patients with DMD, aged between 5 and 11 years. It will evaluate the safety and tolerability of SMT C1100, and will measure blood concentration levels of the drug as Summit aims to confirm the dose to be used in a subsequent patient proof of concept efficacy trial. The Phase 1b trial will be conducted at up to four NHS hospitals located in the UK and patient recruitment is expected to start shortly.

The Chief Investigator for the trial, Professor Francesco Muntoni, Paediatric Neurologist at Great Ormond Street Hospital and Director of the Dubowitz Neuromuscular Centreadded, "Utrophin is a promising approach for the treatment of all DMD patients, regardless of their genetic mutation. It also has the potential to be complementary to other therapeutics approaches in clinical development and the start of the first patient trial of SMT C1100 is an important moment for the whole DMD community."

Further details about the clinical trial will be made available via www.clinicaltrials.gov and www.clinicaltrialsregister.eu.

- END -

Sounds promising!

1 Nov N+1 Singer 11.00 Buy